

## CURRICULUM VITAE

**NAME:** Joseph A. Sparano, MD, FACP

**DATE UPDATED:** February 24, 2012

**CURRENT ADDRESS & TELEPHONE:**

Montefiore Medical Center – Weiler Division

1825 Eastchester Road, 2 South, Rm 47-48, Bronx, NY 10461

Phone 718-904-2555; Fax 718-904-2892

Email: [jsparano@montefiore.org](mailto:jsparano@montefiore.org) or [Sparano@jimmy.harvard.edu](mailto:Sparano@jimmy.harvard.edu)

**DATE AND PLACE OF BIRTH:** May 24, 1958, New Rochelle, New York

**CITIZENSHIP:** United States

**MEDICAL LICENSURE:** New York, License #161242

**MARITAL STATUS:**

Married, Lori Ann Sparano, October 31, 1982

Children: Alyssa Marie, Born May 16, 1989; Jennifer Ann, Born January 2, 1993

**EDUCATION:**

Sophie Davis School of Biomedical Education, City College of New York

Bachelor of Science, Magna cum Laude

September, 1976 - June, 1980

New York Medical College, Valhalla, New York

M. D.

July, 1980 - June, 1982

**PROFESSIONAL TRAINING:**

St. Vincent's Hospital and Medical Center of New York, New York, NY

Internship in Internal Medicine, July, 1982 - June, 1983

Resident in Internal Medicine, July, 1983 - June, 1985

Chief Resident in Internal Medicine, July, 1985 - June, 1986

Albert Einstein Cancer Center/Montefiore Medical Center

111 East 210th Street, Bronx, New York, 10467

Fellow in Medical Oncology

July, 1986 - June, 1988

**BOARD STATUS:**

Diplomate, American Board of Internal Medicine, Internal Medicine, September 10, 1986

Diplomate, American Board of Internal Medicine, Medical Oncology, November 7, 1989

**INSTITUTIONAL POSITIONS HELD:**

Attending Physician, Department of Oncology, Montefiore Medical Center, Bronx, NY  
July, 1988 - Present

Director, Breast Medical Oncology, Department of Oncology, Montefiore Medical Center  
March, 1993 - Present

Director, Hematology/Oncology Fellowship Training Program  
Albert Einstein Cancer Center/Montefiore Medical Center  
November, 1997 – April, 2003

Director, Albert Einstein Cancer Center Centralized Protocol and Data Management Unit  
July, 2002 – Present

Associate Chairman for Clinical Research, Montefiore Medical Center, Dept. of Oncology  
January 1, 2003 - present

Director, Multi-disciplinary Breast Evaluation Center, Montefiore-Einstein Cancer Center  
June, 2006 – December, 2009

**OTHER POSITIONS HELD:**

Chair, AIDS Committee, Eastern Cooperative Oncology Group  
February, 1998 – June, 2001

Co-Chair, Lymphoma Working Group, AIDS Malignancy Consortium (AMC)  
October, 1999 – December, 2001

Chair, Lymphoma Committee, AMC  
January 2002- January, 2004

Chair, Non-AIDS Defining Malignancy Working Group, AMC  
January 2008-January, 2010

Associate Group Chair, Disease-Oriented Research, Eastern Cooperative Oncology Group  
January, 2001 – present

Co-Chair, Breast Committee, Eastern Cooperative Oncology Group  
March, 2002 – January, 2010

Chair, Breast Committee, Easter Cooperative Oncology Group  
January, 2010 - present

Chair, New York Cancer Consortium  
July, 2005 - present

Vice-Chair, AIDS Malignancy Consortium  
June, 2006 - present

Board of Governors, Eastern Cooperative Oncology Group Foundation, LLC  
June, 2006 - present

**ACADEMIC APPOINTMENTS:**

Instructor in Medicine, Albert Einstein College of Medicine, Bronx, New York  
July, 1988 - June, 1989

Assistant Professor of Medicine, Albert Einstein College of Medicine  
July, 1989 - June, 1994

Associate Professor of Medicine, Albert Einstein College of Medicine  
July, 1994 – June, 2000

Professor of Medicine, Albert Einstein College of Medicine  
July, 2000 – present

Professor of Obstetrics, Gynecology, & Women's Health, Albert Einstein College  
July, 2006 - present

**INSTITUTIONAL COMMITTEES:**

Albert Einstein Cancer Center  
Cancer Center Protocol Review and Monitoring Committee  
July, 1995- June, 1998; January, 2001-present

Chair, Albert Einstein Cancer Center  
Data Safety Monitoring Committee  
January, 2001 – January, 2003  
Member, February 2003-present

Albert Einstein College of Medicine, Committee of Clinical Investigations (IRB)  
July 1999- June, 2002

**EXTERNAL COMMITTEES**

NIH, Subcommittee H, Ad Hoc Reviewer  
January 1997- present

ASCO Program Committee  
January, 2003- January, 2005; January, 2011-present

NIH, Subcommittee A, Ad Hoc Reviewer  
July, 2004- present

Department of Defense Breast Cancer Review Panel  
August, 2008

## **PRIOR PEER REVIEWED FUNDING:**

### **American Cancer Society Career Development Award**

Project Period: July, 1991- June, 1994

Support for career development in developmental therapeutics in breast cancer, lymphoma, and novel agents.

### **Komen Greater NYC (P.I. J. Sparano)**

“Reducing Barriers to Clinical Trial Participation in Latino Women”.

Project Period: 4/1/06-3/31/08

Recruitment of Latino breast cancer clinical trial coordinator to enhance clinical trial participation by minority women.

### **Komen Greater NYC (P.I. J. Sparano)**

“Reducing Barriers to Clinical Trial Participation in Minority Women”.

Project Period: 4/1/08-3/31/10

Recruitment of breast cancer clinical trial recruitment and retention coordinator to enhance clinical trial participation by minority women.

### **NIH N01-CM-62204 (PI: J. Sparano)**

Contract No. HHSN261200622004C

Early Therapeutics Development with Phase II Emphasis

Project Period: 1/1/06-9/30/11

Supported phase I, phase I-II, and phase I-II trials via the New York Cancer Consortium.

## **CURRENT PEER REVIEWED FUNDING**

### **NIH/NCI U10 14758-37 (PI: J. Sparano)**

Eastern Cooperative Oncology Group;

Project Period: 6/1/78-5/31/13

Participation as a main member institution of ECOG that plays key scientific and administrative role in addition to substantial accrual

### **NIH/NCI R01 CA098473-07 (P.I. S. Sebti; co-PI: J. Sparano)**

Targeted Intervention of Breast Oncogenic Pathways

Project Period: 5/1/05-4/30/15

- NCI protocol 5598: A Phase I-II study of tipifarnib plus doxorubicin and cyclophosphamide in patients with locally advanced breast cancer and metastatic breast cancer.
- NCI protocol 7868: A Phase I-II study of tipifarnib plus sequential paclitaxel followed by doxorubicin and cyclophosphamide in patients with locally advanced breast cancer and metastatic breast cancer.
- Phase I-II trial of tricirbine plus sequential paclitaxel followed by doxorubicin and cyclophosphamide in patients with locally advanced breast cancer and metastatic breast cancer.

### **ECOG /Frontier Science NIH/NCI U01 CA21115-37 (PI: R. Comis)**

ECOG Disease & Modality Committee Liaison

Project Period: 05/01/01-4/30/09

Salary support only for Dr. Sparano's role as the liaison for the disease and modality committee chairs.

**NIH/NCI U01 CA131947-04 (PI: R. Mitsuyasu)**

AIDS Malignancy Consortium

Project Period 9/1/08-8/31/13

Participation as a core site and Group Vice-Chair - key scientific and administrative role in addition to accrual.

**NIH/NCI P30 CA 13330-39 (P.I. I.D.Goldman)**

Albert Einstein Cancer Center Core Support

Co PI. J. Sparano

Project Period: 7/1/01-6/30/13

Salary only support for Dr. Sparano's role as the Director of the Clinical Research Program

**HONORS AND AWARDS:**

Bachelor of Science, Magna cum Laude

Sophie Davis School of Biomedical Education, City College of New York

June, 1982

Kevin J. Connorton Resident of the Year Award, St. Vincent's Medical Center, NY, NY

June, 1985

American Cancer Society Regular Clinical Fellowship

July, 1987 - June, 1988

American Cancer Society Career Development Award

July, 1991 - June, 1994

Fellow, American College of Physicians

January, 1994 - present

ECOG Young Investigator Award

June, 2000

Leo Davidoff Society (outstanding teaching), Albert Einstein College of Medicine

June, 2002

Top Doctors, Castle Connolly

2004- present

Spirit of Achievement Award, Einstein National Women's Division

Albert Einstein College of Medicine

May, 2011

**PROFESSIONAL SOCIETIES:**

American College of Physicians (1990)  
American Federation for Clinical Research (1990)  
Eastern Cooperative Oncology Group (1990)  
American Radium Society (1992)  
American Society of Clinical Oncology (1992)  
American Association of Cancer Research (1992)  
American Society of Hematology (1993)

**JOURNALS REVIEWED FOR:**

Cancer, Journal of Clinical Oncology, Journal of Cancer Research and Clinical Oncology, Cancer Chemotherapy and Pharmacology, Medical Oncology and Tumor Pharmacology, American Journal of Clinical Oncology, International Journal of Cancer, Cancer Research, Clinical Cancer Research, Medical Oncology, Gynecologic Oncology, Cancer Investigation, American Journal of Cancer, Annals of Oncology, Annals of Internal Medicine, Journal of Laboratory and Clinical Medicine, Hematologica, New England Journal of Medicine

**EDITORIAL BOARD:**

Clinical Breast Cancer  
Journal of Clinical Oncology

**PRINCIPAL INVESTIGATOR FOR CTEP-SPONSORED or INDUSTRY SPONSORED STUDIES:**

1. PY990: A phase I trial of CAF plus interferon in advanced breast cancer.(published, reference 22)
2. E3292: A phase II trial of 5-FU plus interferon in pancreatic carcinoma.(published, reference 41)
3. E3493: A phase II trial of infusional CDE in poor prognosis lymphoma.(published, reference 52)
4. E1494: A phase II trial of infusional CDE in patients with HIV-associated lymphoma.(published, reference 61)
5. E1194: A phase II trial of cisplatin plus paclitaxel in advanced breast cancer. (published, reference 44)
6. T0054: Phase I trial of dexrazoxane plus doxorubicin and paclitaxel in metastatic breast cancer (published, reference 54)
7. E4195: A phase II trial of doxorubicin plus paclitaxel in advanced breast cancer.(published, reference 60)
8. E1196: A phase II trial of doxorubicin plus docetaxel in advanced breast cancer.(published, reference 62)
9. E2196: A randomized phase III trial of marimastat vs. Placebo in patients with advanced breast cancer responding to conventional chemotherapy.(published, reference 92)
10. E1199: A randomized phase III trial of paclitaxel compared with docetaxel given weekly or every 3 weeks following doxorubicin-cyclophosphamide in women with axillary node positive breast cancer (published, reference 117)
11. P5598: A Phase I-II Study of tipifarnib plus doxorubicin and cyclophosphamide in locally advanced and metastatic breast cancer. (published, reference 125)
12. Doxil-BCA-3001: A randomized controlled study of docetaxel monotherapy or

- DOXIL®/CAELYX® and docetaxel for the treatment of advanced breast cancer (Johnson and Johnson) (Published, reference 137).
13. TAILORx: (Trial Assigning Individualized Options for Treatment) - Program for the Assessment of Clinical Tests (PACCT-1) (Initiated April, 2006 - completed October, 2010).
  14. P7703: Phase I-II trial of vorinostat plus paclitaxel-bevacizumab in metastatic breast cancer. (Published, reference 163).
  15. AMC034: Randomized phase II trial of EPOCH plus concurrent or sequential rituximab in HIV-associated lymphoma. Completed. (Poster Discussion presentation, ASCO 2008; published, reference 102)
  16. AMC045: Phase II trial of cetuximab plus cisplatin, 5-FU, and RT in HIV-associated anal carcinoma. (Completed, abstract submitted to ASCO 2012).



**CO-PRINCIPAL INVESTIGATOR FOR COOPERATIVE GROUP STUDIES (ECOG):**

1. E2197 (Chair: L. Goldstein): A phase III trial of doxorubicin-cyclophosphamide vs. doxorubicin-docetaxel in patients with operable breast cancer and 0-3 positive axillary lymph nodes. (published, reference 121).
2. E3198 (Chair: A. Wolff): A phase II trial of liposomal doxorubicin plus docetaxel ± Herceptin in advanced breast cancer. (published, reference 103).
3. E1103 (Chair: W. Gradishar): A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with metastatic breast cancer. (Submitted, Breast Cancer Research and Treatment)
4. E2103 (Chair: S. Moulder): A randomized phase II trial of trastuzumab and BMS-247550 versus trastuzumab, BMS-247550 and carboplatin in patients with HER2/neu positive metastatic breast cancer. (Published, reference 133).
5. P6205 (Chair: L. Vahdat): A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination with Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients who Have Progressive Disease After First-Line Endocrine Therapy (New York Cancer Consortium). (Published, referenced 123).
6. P7868 (Chair: D. Hershman): Phase I-II trial of tipifarnib plus sequential tipifarnib-AC as neoadjuvant therapy in stage II-III breast cancer (New York Cancer Consortium). (Completed, abstract in preparation, San Antonio Breast Cancer Symposium, 2012)
7. E1104 (Chair: R. Swaby): Phase II trial of vorinostat in trastuzumab-refractory Her2/neu positive breast cancer. (Manuscript in preparation)
8. E3205 (Chair: M. Garg): Phase II trial of cetuximab plus cisplatin, 5-FU, and RT in anal carcinoma. In Progress.

**COURSE DIRECTOR:**

1. Annual ECOG Young Investigator Symposium. 2001- present.
2. New York Cancer Consortium Annual Developmental Therapeutics Symposium. 2006-present ([www.newyorkcancersortium.org](http://www.newyorkcancersortium.org)).

## ORIGINAL ARTICLES

*(mentored student, resident, fellow, faculty indicated in underlined italics) :*

1. **Sparano J**, Ferranti E. The acquired immunodeficiency syndrome and nonmenstrual toxic shock syndrome. *Ann Intern Med.* 1986 Aug;105(2):300-1. No abstract available. PubMed [citation] PMID: 3729216
2. **Sparano J**, Chang J, Trasi S, Bonanno C. Treatment of the Budd-Chiari syndrome with percutaneous transluminal angioplasty. Case report and review of the literature. *Am J Med.* 1987 Apr;82(4):821-8. Review. PubMed [citation] PMID: 2952007
3. **Sparano J**, Ramirez M, Wiernik PH. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. *Cancer.* 1990 Mar 1;65(5):1072-3. PubMed [citation] PMID: 2302658
4. **Sparano JA**, Wiernik PH. Toxicity of etoposide, doxorubicin, and cisplatin in gastric cancer. *J Clin Oncol.* 1990 May;8(5):938-9. No abstract available. PubMed [citation] PMID: 2332775
5. **Sparano JA**, Schwartz EL, Salva KM, Pizzillo MF, Wadler S, Wiernik PH. Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. *Am J Clin Oncol.* 1990 Oct;13(5):374-8. PubMed [citation] PMID: 2220657
6. Sznol M, Mier JW, **Sparano J**, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP, et al. A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. *J Biol Response Mod.* 1990 Dec;9(6):529-37. PubMed [citation] PMID: 2074439
7. **Sparano JA**, Beckwith JB, Mitsudo S, Wiernik PH. Complete remission in refractory anaplastic adult Wilms' tumor treated with cisplatin and etoposide. *Cancer.* 1991 Feb 15;67(4):956-9. PubMed [citation] PMID: 1846771
8. Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, **Sparano J**, Fisher RI, Weiss G, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. *J Clin Oncol.* 1991 Apr;9(4):641-8. PubMed [citation] PMID: 2066760
9. **Sparano JA**, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. *Cancer.* 1991 Oct 1;68(7):1538-44. PubMed [citation] PMID: 1893354
10. Gucalp R, Ciobanu N, **Sparano J**, Motyl M, Carlisle P, Wiernik PH. Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. *Cancer.* 1991 Oct 15;68(8):1842-4. PubMed [citation] PMID: 1655226

11. Ciobanu N, Weinberg V, **Sparano JA**, Zervos G, Walewski J, Spivack M, Wiernik PH. Experience with autologous bone marrow harvesting and transfusion of marrow-derived red cells. *Transfusion*. 1992 Mar-Apr;32(3):231-4. PubMed [citation] PMID: 1557804
12. **Sparano JA**, Gucalp R, Llena JF, Moser FG, Wiernik PH. Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. *J Neurooncol*. 1992 May;13(1):91-100. PubMed [citation] PMID: 1613541
13. **Sparano JA**, O'Boyle K. The potential role for biological therapy in the treatment of breast cancer. *Semin Oncol*. 1992 Jun;19(3):333-41. Review. No abstract available. PubMed [citation] PMID: 1609298
14. **Sparano JA**, Wadler S. Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies. *Adv Exp Med Biol*. 1993;339:125-31; discussion 165-7. Review. No abstract available. PubMed [citation] PMID: 8178711
15. **Sparano JA**, Wadler S, Schwartz EL, Diasio R. Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. *Int J Clin Pharmacol Res*. 1993;13(1):1-9. Review. PubMed [citation] PMID: 8509231
16. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. *J Clin Oncol*. 1993 Apr;11(4):661-70. PubMed [citation] PMID: 8478661
17. **Sparano JA**, Brandt LJ, Dutcher JP, DuBois JS, Atkins MB. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2. *Ann Intern Med*. 1993 Apr 15;118(8):617-8. No abstract available. PubMed [citation] PMID: 8452327
18. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, et al. Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. *J Immunother Emphasis Tumor Immunol*. 1993 May 4;13(4):275-81. PubMed [citation] PMID: 8101452
19. **Sparano JA**, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen. *Blood*. 1993 May 15;81(10):2810-5. PubMed [citation] PMID: 8490187
20. **Sparano JA**, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. *J Clin Oncol*. 1993 Jun;11(6):1071-9. PubMed [citation] PMID: 8501493

21. **Sparano JA**, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. *J Clin Oncol*. 1993 Aug;11(8):1609-17. PubMed [citation] PMID: 8336197
22. **Sparano JA**, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. *Cancer Res*. 1993 Aug 1;53(15):3509-12. PubMed [citation] PMID: 8339255
23. **Sparano JA**, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. *J Clin Oncol*. 1993 Oct;11(10):1969-77. PubMed [citation] PMID: 8410122
24. Wiernik PH, Sklarin NT, Dutcher JP, **Sparano JA**, Greenwald ES. Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer. *Med Oncol*. 1994;11(3-4):121-5. PubMed [citation] PMID: 7633831
25. Gucalp R, Sparano J, Dutcher JP, Wiernik PH. Introduction to bone marrow transplant symposium held at the Albert Einstein Cancer Center at Bronx, NY, USA, March 23 to 25, 1994. *Med Oncol*. 1994;11(2):31-3. No abstract available. PubMed [citation] PMID: 7850261
26. Wadler S, Tenteromano L, Cazenave L, **Sparano JA**, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. *Cancer Chemother Pharmacol*. 1994;34(3):266-9. PubMed [citation] PMID: 8004762
27. **Sparano JA**, Wiernik PH, Strack M, Leaf A, Becker NH, Sarta C, Carney D, Elkind R, Shah M, Valentine ES, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. *Leuk Lymphoma*. 1994 Jul;14(3-4):263-71. PubMed [citation] PMID: 7950915
28. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, **Sparano JA**, Fisher RI, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. *J Clin Oncol*. 1994 Aug;12(8):1553-60. PubMed [citation] PMID: 8040667
29. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, **Sparano JA**, Tormey DC, Wood WC. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. *JAMA*. 1994 Aug 17;272(7):540-5. No abstract available. Erratum in: *JAMA* 1995 Feb

1;273(5):378. PubMed [citation] PMID: 8046809

30. **Sparano JA**, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. *J Immunother Emphasis Tumor Immunol.* 1994 Oct;16(3):216-23. PubMed [citation] PMID: 7834121

31. Sledge GW Jr, Robert N, **Sparano JA**, Cobeligh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. *Semin Oncol.* 1994 Oct;21(5 Suppl 8):15-8. PubMed [citation] PMID: 7939756

32. Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, Wiernik PH. A distinct coagulopathy associated with interleukin-2 therapy. *Br J Haematol.* 1994 Dec;88(4):892-4. PubMed [citation] PMID: 7819116

33. **Khalil A**, Ciobanu N, **Sparano JA**, Gucalp R, Dutcher JP, Wiernik PH. Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies. *Bone Marrow Transplant.* 1995 Jan;15(1):93-7. PubMed [citation] PMID: 7742763

34. Sledge GW Jr, Robert N, **Sparano JA**, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. *Semin Oncol.* 1995 Jun;22(3 Suppl 6):105-8. Review. PubMed [citation] PMID: 7597425

35. **Sparano JA**. Treatment of AIDS-related lymphomas. *Curr Opin Oncol.* 1995 Sep;7(5):442-9. Review. PubMed [citation] PMID: 8541390

36. **Levy RJ**, **Sparano JA**, Khan G. Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. *Med Oncol.* 1995 Dec;12(4):219-22. PubMed [citation] PMID: 8832525

37. **Sparano JA**, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. *Curr Opin Oncol.* 1996 Sep;8(5):392-9. Review. PubMed [citation] PMID: 8914806

38. **Sparano JA**, Robert N, Silverman P, Lazarus H, Malik U, Venkatraj U, Sarta C. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma. *J Clin Oncol.* 1996 Sep;14(9):2576-83. Erratum in: *J Clin Oncol* 1996 Dec;14(12):3175. PubMed [citation] PMID: 8823338

39. Rosenblatt R, Fineberg SA, **Sparano JA**, Kaleya RN. Stereotactic core needle biopsy of multiple sites in the breast: efficacy and effect on patient care. *Radiology.* 1996 Oct;201(1):67-70. PubMed [citation] PMID: 8816522

40. **Sparano JA**, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B,

Ratech H, Dutcher JP. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. *J Clin Oncol.* 1996 Nov;14(11):3026-35. PubMed [citation] PMID: 8918501

41. **Sparano JA**, Lipsitz S, Wadler S, Hansen R, Bushunow PW, Kirkwood J, Flynn PJ, Dutcher JP, Benson AB. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. *Am J Clin Oncol.* 1996 Dec;19(6):546-51. PubMed [citation] PMID: 8931668

42. **Sparano JA**, Hu X, Wiernik PH, Sarta C, Reddy DM, Hanau L, Henry DH. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. *J Natl Cancer Inst.* 1997 Feb 19;89(4):301-7. PubMed [citation] PMID: 9048834

43. Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. *Clin Cancer Res.* 1997 Apr;3(4):565-72. PubMed [citation] PMID: 9815721

44. **Sparano JA**, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. *J Clin Oncol.* 1997 May;15(5):1880-4. PubMed [citation] PMID: 9164198

45. Kabat GC, Chang CJ, **Sparano JA**, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. *Cancer Epidemiol Biomarkers Prev.* 1997 Jul;6(7):505-9. PubMed [citation] PMID: 9232337

46. Sparano J. Chemotherapy for AIDS-related lymphomas. *N Engl J Med.* 1997 Oct 16;337(16):1173; author reply 1173-4. No abstract available. PubMed [citation] PMID: 9340512

47. Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R, Carlisle PS, Sparano J, Parker P, Salata RA. Determination and validation of a predictive model for *Clostridium difficile* diarrhea in hospitalized oncology patients. *Ann Oncol.* 1998 Mar;9(3):307-11. PubMed [citation] PMID: 9602265

48. Iskaros BF, Hu X, **Sparano JA**, Fineberg SA. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. *J Surg Oncol.* 1998 Jun;68(2):107-12. PubMed [citation] PMID: 9624040

49. **Sparano JA**, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in

patients with HIV-associated non-Hodgkin's lymphoma. *Med Oncol*. 1998 Apr;15(1):50-7. PubMed [citation] PMID: 9643531

50. Wiernik PH, Dutcher JP, Einzig AI, Sparano J, Frank M, Friedenber W. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. *Cancer J Sci Am*. 1998 Jul-Aug;4(4):254-60. PubMed [citation] PMID: 9689984

51. **Sparano JA**. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. *Semin Oncol*. 1998 Aug;25(4 Suppl 10):66-71. Review. PubMed [citation] PMID: 9768827

52. Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, **Sparano JA**, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon. *Med Oncol*. 1998 Sep;15(3):191-8. PubMed [citation] PMID: 9819796

53. **Sparano JA**. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies. *Semin Oncol*. 1998 Dec;25(6 Suppl 13):10-5. PubMed [citation] PMID: 9865686

54. **Sparano JA**, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. *J Clin Oncol*. 1999 Mar;17(3):880-6. PubMed [citation] PMID: 10071279

55. Racevskis J, Dill A, **Sparano JA**, Ruan H. Molecular cloning of LMO41, a new human LIM domain gene. *Biochim Biophys Acta*. 1999 Apr 14;1445(1):148-53. PubMed [citation] PMID: 10209267

56. Seno R, **Sparano JA**, Fineberg SA. Gross and histologic features of locally advanced breast cancer after neoadjuvant chemotherapy. *Anat Pathol*. 1998;3:169-80. No abstract available. PubMed [citation] PMID: 10389584

57. **Sparano JA**. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. *Semin Oncol*. 1999 Jun;26(3 Suppl 9):14-9. Review. PubMed [citation] PMID: 10426454

58. **Sparano JA**, Anand K, Desai J, Mitnick RJ, Kalkut GE, Hanau LH. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. *J Acquir Immune Defic Syndr*. 1999 Aug 1;21 Suppl 1:S18-22. PubMed [citation] PMID: 10430213

59. **Desai J**, Mitnick RJ, Henry DH, Llana J, **Sparano JA**. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma. *Cancer*. 1999 Nov 1;86(9):1840-7. PubMed [citation] PMID: 10547559

60. **Sparano JA**, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. *J Clin Oncol.* 1999 Dec;17(12):3828-34. PubMed [citation] PMID: 10577856
61. **Sparano JA**, Rajdev L. Taxane-based therapy for breast cancer: combination or sequential therapy? *Cancer Invest.* 2000;18(5):498-500. No abstract available. PubMed [citation] PMID: 10834036
62. **Sparano JA**, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. *J Clin Oncol.* 2000 Jun;18(12):2369-77. PubMed [citation] PMID: 10856096
63. Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, **Sparano JA**, Lisanti MP, Pestell RG. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. *Front Biosci.* 2000 Dec 1;5:D938-61. Review. PubMed [citation] PMID: 11102317
64. **Sparano JA**, Wolff AC, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. *Lancet.* 2000 Dec 9;356(9246):1947-8. No abstract available. PubMed [citation] PMID: 11130520
65. Ambinder RF, **Sparano JA**. Primary central nervous system lymphoma. *Cancer Treat Res.* 2001;104:231-46. Review. No abstract available. PubMed [citation] PMID: 11191129
66. **Sparano JA**, Kalkut G. Special considerations regarding antiretroviral therapy and infection prophylaxis in the HIV-infected individual with cancer. *Cancer Treat Res.* 2001;104:347-66. Review. No abstract available. PubMed [citation] PMID: 11191134
67. **Sparano JA**. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. *Semin Oncol.* 2001 Feb;28(1 Suppl 3):20-7. Review. PubMed [citation] PMID: 11301371
68. Sharma A, Mani S, Hanna N, Guha C, Vikram B, Weichselbaum RR, **Sparano J**, Sood B, Lee D, Regine W, Muhodin M, Valentino J, Herman J, Desimone P, Arnold S, Carrico J, Rockich AK, Warner-Carpenter J, Barton-Baxter M. Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. *Hum Gene Ther.* 2001 Jun 10;12(9):1109-31. No abstract available. PubMed [citation] PMID: 11399232
69. **Sparano JA**, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. *J Clin Oncol.* 2001 Jun 15;19(12):3117-25. PubMed [citation] PMID: 11408509



70. **Sparano JA**. Clinical aspects and management of AIDS-related lymphoma. *Eur J Cancer*. 2001 Jul;37(10):1296-305. Review. PubMed [citation] PMID: 11423261
71. **Sparano JA**, Winer EP. Liposomal anthracyclines for breast cancer. *Semin Oncol*. 2001 Aug;28(4 Suppl 12):32-40. Review. PubMed [citation] PMID: 11552228
72. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, **Sparano JA**. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. *Recent Results Cancer Res*. 2002;159:149-53. PubMed [citation] PMID: 11785839
73. **Sparano JA**. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. *Clin Breast Cancer*. 2000 Apr;1(1):32-40; discussion 41-2. Review. PubMed [citation] PMID: 11899388
74. **Kalfon B**, Fineberg S, Gu Y, Anand K, Dalal A, Jones J, **Sparano JA**. Microvessel density and p53 overexpression in young women with breast cancer: a case-control study. *Clin Breast Cancer*. 2001 Apr;2(1):67-72. PubMed [citation] PMID: 11899385
75. **Salman HS**, Tanaka K, **Sparano JA**. Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. *Clin Breast Cancer*. 2002 Jan;2(4):299-303. PubMed [citation] PMID: 11899362
76. **Sparano JA**, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. *Drug Saf*. 2002;25(5):301-11. Review. PubMed [citation] PMID: 12020170
77. **Sparano JA**, Weller E, Nazeer T, Habermann T, Traynor AE, Manalo J, Cassileth P. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). *Blood*. 2002 Sep 1;100(5):1634-40. PubMed [citation] PMID: 12176882
78. Miller KD, Gradishar W, Schuchter L, **Sparano JA**, Cobleigh M, Robert N, Rasmussen H, Sledge GW. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. *Ann Oncol*. 2002 Aug;13(8):1220-4. PubMed [citation] PMID: 12181245
79. Spina M, **Sparano JA**, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. *AIDS*. 2003 Jan 3;17(1):137-8. No abstract available. PubMed [citation] PMID: 12478085
80. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, **Sparano JA**, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by

docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. *Mol Cancer Ther.* 2002 Nov;1(13):1191-200. PubMed [citation] PMID: 12479700

81. **Li T**, **Sparano JA**. Inhibiting Ras signaling in the therapy of breast cancer. *Clin Breast Cancer.* 2003 Feb;3(6):405-16; discussion 417-20. Review. PubMed [citation] PMID: 12636885

82. **Abbasi MR**, **Sparano JA**, Sarta C, Wiernik PH. Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma. *Med Oncol.* 2003;20(1):53-8. PubMed [citation] PMID: 12665685

83. **Makower D**, **Sparano JA**, Wadler S, Fehn K, Landau L, Wissel P, Versola M, Mani S. A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. *Cancer Invest.* 2003 Apr;21(2):177-84. PubMed [citation] PMID: 12743982

84. **Salman H**, **Perez A**, **Sparano JA**, Ratech H, Negassa A, Hopkins U, Villani G, Fuks J, Wiernik PH. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma. *Am J Clin Oncol.* 2003 Aug;26(4):338-43. PubMed [citation] PMID: 12902881

85. **Sparano JA**. Human immunodeficiency virus associated lymphoma. *Curr Opin Oncol.* 2003 Sep;15(5):372-8. Review. PubMed [citation] PMID: 12960519

86. **Gaba AG**, **Sparano JA**. Metastatic carcinoma: an unusual cause of focal brain lesions in HIV infection. *AIDS Read.* 2003 Nov;13(11):547-8, 551-3, 558-9. PubMed [citation] PMID: 14649625

87. **Sparano JA**, Gray R, Giantonio B, O'Dwyer P, Comis RL; Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. *Clin Cancer Res.* 2004 Feb 15;10(4):1206-11. PubMed [citation] PMID: 14977816

88. **Raff JP**, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, Hopkins U, Sarta C, **Sparano JA**. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. *Clin Breast Cancer.* 2004 Feb;4(6):420-7. PubMed [citation] PMID: 15023243

89. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, **Sparano JA**, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. *Clin Cancer Res.* 2004 Mar 15;10(6):1971-5. PubMed [citation] PMID: 15041714

90. **Sparano JA**, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. Phase II trial of infusional cyclophosphamide, doxorubicin,

and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). *J Clin Oncol*. 2004 Apr 15;22(8):1491-500. PubMed [citation] PMID: 15084622

91. Spina M, Jaeger U, **Sparano JA**, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. *Blood*. 2005 Mar 1;105(5):1891-7. Epub 2004 Nov 18. PubMed [citation] PMID: 15550484

92. **Sparano JA**, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. *J Clin Oncol*. 2004 Dec 1;22(23):4683-90. Erratum in: *J Clin Oncol*. 2005 Jan 1;23(1):248. PubMed [citation] PMID: 15570070

93. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, **Sparano JA**, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. *Semin Oncol*. 2004 Dec;31(6 Suppl 13):53-90. Review. PubMed [citation] PMID: 15717738

94. Robert NJ, Vogel CL, Henderson IC, **Sparano JA**, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. *Semin Oncol*. 2004 Dec;31(6 Suppl 13):106-46. Review. PubMed [citation] PMID: 15717740

95. Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J; American Society of Clinical Oncology. ACCO: ASCO core curriculum outline. *J Clin Oncol*. 2005 Mar 20;23(9):2049-77. Epub 2005 Feb 22. No abstract available. PubMed [citation] PMID: 15728218

96. Kaplan LD, Lee JY, Ambinder RF, **Sparano JA**, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood*. 2005 Sep 1;106(5):1538-43. Epub 2005 May 24. PubMed [citation] PMID: 15914552, PMCID: PMC1895225

97. O'Regan RM, Von Roenn JH, Carlson RW, Malik U, **Sparano JA**, Staradub V, Khan S, Jovanovic B, Morrow M, Gradishar WJ. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. *Clin Breast Cancer*. 2005 Jun;6(2):163-8. PubMed [citation] PMID: 16001995

98. **Sparano JA**. Cancer in AIDS. *Curr Opin Oncol*. 2005 Sep;17(5):446. No abstract available. PubMed [citation] PMID: 16093793
99. **Sparano JA**, Negassa A, Lansigan E, Locke R, De Silva CR, Wiernik PH. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. *Med Oncol*. 2005;22(3):257-67. PubMed [citation] PMID: 16110137
100. Gormley RP, Madan R, Dulau AE, Xu D, Tamas EF, Bhattacharyya PK, LeValley A, Xue X, Kumar P, Sparano J, Ramesh KH, Pulijaal V, Cannizzaro L, Walsh D, Ioachim HL, Ratech H. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. *Am J Clin Pathol*. 2005 Nov;124(5):790-8. PubMed [citation] PMID: 16203284
101. **Parekh S**, Ratech H, **Sparano JA**. Human immunodeficiency virus-associated lymphoma. *Clin Adv Hematol Oncol*. 2003 May;1(5):295-301. Review. PubMed [citation] PMID: 16224426
102. **Parekh S**, Hebert T, Ratech H, Sparano J. Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum. *J Clin Oncol*. 2005 Nov 1;23(31):8116-7. No abstract available. PubMed [citation] PMID: 16258111
103. Madan R, Gormley R, Dulau A, Xu D, Walsh D, Ramesh KH, Cannizzaro L, Tamas EF, Kumar P, Sparano J, LeValley A, Xue X, Bhattacharyya PK, Ioachim HL, Ratech H. AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. *Mod Pathol*. 2006 Mar;19(3):438-46. PubMed [citation] PMID: 16444194
104. Heck JF, Sparano JM. A classification system for the assessment of lumbar pain in athletes. *J Athl Train*. 2000 Apr;35(2):204-11. PubMed [citation] PMID: 16558632, PMCID: PMC1323419
105. **Sparano JA**, Fazzari MJ, Childs G. Clinical application of molecular profiling in breast cancer. *Future Oncol*. 2005 Aug;1(4):485-96. Review. PubMed [citation] PMID: 16556025
106. Zucker S, Wang M, **Sparano JA**, Gradishar WJ, Ingle JN, Davidson NE; Eastern Cooperative Oncology Group. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. *Clin Breast Cancer*. 2006 Feb;6(6):525-9. PubMed [citation] PMID: 16595036
107. **Li T**, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, **Sparano JA**, Lisanti MP. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. *Am J Pathol*. 2006 Jun;168(6):1998-2013. PubMed [citation] PMID: 16723714, PMCID: PMC1606619

108. **Sparano JA**, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebt SM. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. *J Clin Oncol*. 2006 Jul 1;24(19):3013-8. Epub 2006 Jun 12. PubMed [citation] PMID: 16769985
109. **Rajdev L**, Goldberg G, Hopkins U, **Sparano JA**. A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. *Med Oncol*. 2006;23(3):369-76. PubMed [citation] PMID: 17018894
110. **Sparano JA**. TAILORx: trial assigning individualized options for treatment (Rx). *Clin Breast Cancer*. 2006 Oct;7(4):347-50. No abstract available. PubMed [citation] PMID: 17092406
111. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, **Sparano JA**, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol*. 2007 May 20;25(15):2127-32. PubMed [citation] PMID: 17513820
112. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, **Sparano J**, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curv© H. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. *J Clin Oncol*. 2007 Aug 10;25(23):3415-20. Epub 2007 Jul 2. PubMed [citation] PMID: 17606972
113. **Sparano JA**. HIV-associated lymphoma: the evidence for treating aggressively but with caution. *Curr Opin Oncol*. 2007 Sep;19(5):458-63. Review. PubMed [citation] PMID: 17762571
114. **Moadel AB**, **Shah C**, Wylie-Rosett J, Harris MS, Patel SR, Hall CB, **Sparano JA**. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. *J Clin Oncol*. 2007 Oct 1;25(28):4387-95. Epub 2007 Sep 4. PubMed [citation] PMID: 17785709
115. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, **Sparano JA**, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. *Clin Cancer Res*. 2007 Oct 15;13(20):6168-74. PubMed [citation] PMID: 17947483
116. **Sparano JA**, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. *J Clin Oncol*. 2008 Feb 10;26(5):721-8. Review. PubMed [citation] PMID: 18258979

117. **Sparano JA**, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. *N Engl J Med*. 2008 Apr 17;358(16):1663-71. Erratum in: *N Engl J Med*. 2008 Jul 3;359(1):106. *N Engl J Med*. 2009 Apr 16;360(16):1685. PubMed [citation] PMID: 18420499, PMCID: PMC2743943
118. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, **Sparano JA**. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. *J Clin Oncol*. 2008 May 20;26(15):2473-81. Erratum in: *J Clin Oncol*. 2008 Jul 10;26(20):3472. Perez, Edith D [corrected to Perez, Edith A]. PubMed [citation] PMID: 18487567
119. **Li T**, **Sparano JA**. Farnesyl transferase inhibitors. *Cancer Invest*. 2008 Aug;26(7):653-61. No abstract available. PubMed [citation] PMID: 18665473
120. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, **Sparano JA**. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. *J Clin Oncol*. 2008 Sep 1;26(25):4063-71. Epub 2008 Aug 4. Erratum in: *J Clin Oncol*. 2009 Jul 20;27(21):3566. PubMed [citation] PMID: 18678838, PMCID: PMC2654377
121. Goldstein LJ, O'Neill A, **Sparano JA**, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. *J Clin Oncol*. 2008 Sep 1;26(25):4092-9. Epub 2008 Aug 4. PubMed [citation] PMID: 18678836, PMCID: PMC2654376
122. Arteaga CL, O'Neill A, Moulder SL, Pins M, **Sparano JA**, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. *Clin Cancer Res*. 2008 Oct 1;14(19):6277-83. PubMed [citation] PMID: 18829509, PMCID: PMC2925197
123. **Li T**, Christos PJ, **Sparano JA**, Hershman DL, Hoschander S, O'Brien K, Wright JJ, Vahdat LT. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. *Ann Oncol*. 2009 Apr;20(4):642-7. Epub 2009 Jan 19. PubMed [citation] PMID: 19153124, PMCID: PMC2660860
124. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, **Sparano J**, Lee J, Ambinder R, Campbell N, Lairmore M; AIDS Malignancy Consortium. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. *PLoS One*. 2009;4(2):e4420. Epub 2009 Feb 10. PubMed [citation]

PMID: 19204798, PMCID: PMC2636875

125. **Sparano JA**, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. *Clin Cancer Res*. 2009 Apr 15;15(8):2942-8. Epub 2009 Apr 7. PubMed [citation] PMID: 19351752, PMCID: PMC2785076

126. **Sparano JA**, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. *Breast Cancer Res Treat*. 2010 Feb;119(3):511-27. Epub 2009 Jun 14. PubMed [citation] PMID: 19526354

127. **Sparano JA**, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II... *J Clin Oncol*. 2009 Sep 20;27(27):4522-9. Epub 2009 Aug 17. PubMed [citation] PMID: 19687336

128. **Raab R, Sparano JA**, Ocean AJ, Christos P, Ramirez M, Vinciguerra V, Kaubisch A. A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. *Am J Clin Oncol*. 2010 Feb;33(1):61-5. PubMed [citation] PMID: 19738454

129. **Lam AP, Sparano JA**, Vinciguerra V, Ocean AJ, Christos P, Hochster H, Camacho F, Goel S, Mani S, Kaubisch A. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. *Am J Clin Oncol*. 2010 Apr;33(2):121-4. PubMed [citation] PMID: 19738452

130. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, **Sparano JA**, Bhatia K, Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. *J Clin Oncol*. 2009 Oct 20;27(30):5039-48. Epub 2009 Sep 14. PubMed [citation] PMID: 19752343, PMCID: PMC2799056

131. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, et al. Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. *J Oncol*. 2009;2009:871250. Epub 2009 Oct 25. PubMed

[citation] PMID: 19865486, PMCID: PMC2766507

132. **Sparano JA**, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. *Clin Cancer Res*. 2009 Dec 15;15(24):7693-7700. Epub .PubMed [citation] PMID: 19996222

133. **Moulder S**, Li H, Wang M, Gradishar WJ, Perez EA, **Sparano JA**, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. *Breast Cancer Res Treat*. 2010 Feb;119(3):663-71. PubMed [citation] PMID: 20012354, PMCID: PMC3133687

134. **Sparano JA**, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. *Breast Cancer Res Treat*. 2010 Apr;120(2):273-84. Epub 2009 Dec 19. Review. PubMed [citation] PMID: 20024613

135. **Sparano JA**, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. *Blood*. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18. PubMed [citation] PMID: 20023215, PMCID: PMC2858478

136. **Sparano JA**, Solin LJ. Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. *J Clin Oncol*. 2010 Apr 1;28(10):1625-7. Epub 2010 Jan 11. No abstract available. PubMed [citation] PMID: 20065178

137. Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, **Sparano JA**, Davidson NE. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. *Breast Cancer Res Treat*. 2010 May;121(1):111-20. Epub 2010 Mar 24. PubMed [citation] PMID: 20333545, PMCID: PMC3112234

138. **Chuang E**, Wiener N, Christos P, Kessler R, Cobham M, Donovan D, Goldberg GL, Caputo T, Doyle A, Vahdat L, **Sparano JA**. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. *Ann Oncol*. 2010 Oct;21(10):2075-80. Epub 2010 Mar 31. PubMed [citation] PMID: 20357034, PMCID: PMC2980936

139. **Sparano JA**. Is there a role for ovarian function suppression in operable breast cancer? *Breast Cancer Res Treat*. 2010 Aug;123(1):311-3. Epub 2010 Apr 6. No



abstract available. PubMed [citation] PMID: 20369285

140. **Sparano JA**, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*. 2010 Jul 10;28(20):3256-63. Epub 2010 Jun 7. PubMed [citation] PMID: 20530276, PMCID: PMC2903325
141. **Cianfrocca M**, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, **Sparano JA**. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. *Cancer*. 2010 Aug 15;116(16):3969-77. PubMed [citation] PMID: 20564162, PMCID: PMC3157242
142. **Sparano JA**, Fazzari M, Kenny PA. Clinical application of gene expression profiling in breast cancer. *Surg Oncol Clin N Am*. 2010 Jul;19(3):581-606. Review. PubMed [citation] PMID: 20620929
143. **Blank SV**, Christos P, Curtin JP, Goldman N, Runowicz CD, **Sparano JA**, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. *Gynecol Oncol*. 2010 Dec;119(3):451-6. Epub 2010 Sep 15. PubMed [citation] PMID: 20837357
144. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, **Sparano JA**. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. *Cancer*. 2011 Jan 15;117(2):336-42. doi: 10.1002/cncr.25584. Epub 2010 Sep 22. PubMed [citation] PMID: 20862746, PMCID: PMC3010462
145. **Ocean AJ**, Christos P, **Sparano JA**, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. *Cancer Chemother Pharmacol*. 2011 Aug;68(2):379-88. Epub 2010 Oct 28. PubMed [citation] PMID: 20981545
146. Roche H, Conte P, Perez EA, **Sparano JA**, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. *Breast Cancer Res Treat*. 2011 Feb;125(3):755-65. Epub 2010 Dec 3. PubMed [citation] PMID: 21128114
147. **Cianfrocca M**, Lee S, Von Roenn J, Rudek MA, Dezube BJ, Krown SE, **Sparano JA**. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in

patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. *Cancer Chemother Pharmacol*. 2011 Oct;68(4):827-33. Epub 2011 Jan 5. PubMed [citation] PMID: 21207228, PMCID: PMC3112249

148. ***Ocean AJ***, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, **Sparano JA**, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. *Clin Colorectal Cancer*. 2010 Dec;9(5):290-6. PubMed [citation] PMID: 21208843

149. ***Rajdev L***, Negassa A, Dai Q, Goldberg G, Miller K, **Sparano JA**. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2011 Nov;68(5):1119-24. Epub 2011 Mar 4. PubMed [citation] PMID: 21373895

150. ***Andreopoulou E***, **Sparano JA**. Seeing red: anthracyclines for breast cancer. *Oncology (Williston Park)*. 2011 Feb;25(2):128, 131, 134. No abstract available. PubMed [citation] PMID: 21456383

151. Goss PE, Ingle JN, **Alv©s-Mart√≠nez JE**, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winqvist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med*. 2011 Jun 23;364(25):2381-91. Epub 2011 Jun 4. Erratum in: *N Engl J Med*. 2011 Oct 6;365(14):1361. PubMed [citation] PMID: 21639806

152. Gucalp A, **Sparano JA**, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina TA. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. *Clin Breast Cancer*. 2011 Oct;11(5):306-11. Epub 2011 May 3. PubMed [citation] PMID: 21729667, PMCID: PMC3222913

153. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28. PubMed [citation] PMID: 21802721, PMCID: PMC3163848

154. Mayer EL, Baurain JF, **Sparano J**, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. *Clin Cancer Res*. 2011 Nov 1;17(21):6897-904. Epub 2011 Sep 8. PubMed [citation] PMID: 21903773

155. **Sparano JA**, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL,

- Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. *Clin Cancer Res*. 2011 Nov 15;17(22):7194-203. Epub 2011 Sep 20. PubMed [citation] PMID: 21933890
156. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011 Oct 6;365(14):1273-83. PubMed [citation] PMID: 21991949, PMCID: PMC3268553
157. Giricz O, Calvo V, Pero SC, Krag DN, **Sparano JA**, Kenny PA. GRB7 is required for triple-negative breast cancer cell invasion and survival. *Breast Cancer Res Treat*. 2011 Oct 18. [Epub ahead of print] PubMed [citation] PMID: 22005836
158. **Sparano J**. Joseph Sparano on gene expression assays for breast cancer. *Oncology (Williston Park)*. 2011 Sep;25(10):947. No abstract available. PubMed [citation] PMID: 22010394
159. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet*. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19. Review. PubMed [citation] PMID: 22019144, PMCID: PMC3254252
160. Finn RS, Bengala C, Ibrahim N, Roche H, **Sparano J**, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. *Clin Cancer Res*. 2011 Nov 1;17(21):6905-13. Epub 2011 Oct 25. PubMed [citation] PMID: 22028489
161. **Sparano JA**, Strickler HD. Breast cancer patients who are obese at diagnosis: *alea iacta est?* or "is the die cast"? *Oncology (Williston Park)*. 2011 Oct;25(11):1002, 1004, 1007. No abstract available. PubMed [citation] PMID: 22106550
162. **Barta SK**, Lee JY, Kaplan LD, Noy A, **Sparano JA**. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. *Cancer*. 2011 Dec 16. doi: 10.1002/cncr.26723. [Epub ahead of print] PubMed [citation] PMID: 22180164
163. **Ramaswamy B**, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, **Sparano JA**. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. *Breast Cancer Res Treat*. 2011 Dec 27.

[Epub ahead of print]PubMed [citation] PMID: 22200869

164. **Sparano JA**, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. J Natl Cancer Inst. 2012 Jan 16. [Epub ahead of print]PubMed [citation] PMID: 22250182

165. **Petrich AM**, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, **Sparano JA**, Parekh S. Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL. Clin Cancer Res. 2012 Feb 14. [Epub ahead of print]PubMed [citation] PMID: 22338016

#### **BOOKS EDITED:**

1. **Sparano JA (ed). Cancer Treatment and Research: HIV-Associated Malignancies.** Kluwer Academic Publishers, Norwell, MA, 2001.

#### **BOOK CHAPTERS:**

*(mentored student, resident, fellow, faculty indicated in underlined italics) :*

1. **Sparano JA**, Dutcher, JP. High dose Interleukin-2 Therapy of Malignant Melanoma. In: Atkins, MB, Mier, J (eds) **Therapeutic Applications of Interleukin-2.** Marcell Decker, Inc, New York, 1993, pp 99-117
2. **Sparano JA**, Wadler, S. Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies. In: Rustum, YM (ed). **Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation.** Plenum Press, New York, 1993, pp 125-131.
3. **Sparano JA**, Ciobanu N. Solid Tumors. In: Treleaven J & Wiernik PH. **A Color Atlas and Text of Bone Marrow Transplantation.** Times Mirror International Publishers Limited, London, 1995, pp 77-100.
4. **Sparano JA**, Dutcher JP, Wiernik PH. Low-dose IL-2 for renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WS, Coffey DS. **Comprehensive Textbook of Urologic Oncology,** William & Wilkins, 1995, pp 248-254.
5. Seno R, **Sparano JA**, Fineberg SA. Gross and histologic features of locally advanced breast cancer. In Fechner RE, Rosen PP (ed). **Anatomic Pathology:** 1998 (Vol 3). 3, pp 169-180.
6. Etkind P, **Sparano JA.** Breast Cancer Prevention. In: **Breast Cancer.** Roses D (ed). WB Saunders, 1999, pp 58-73.
7. **Sparano JA.** Drug-Disease Interactions – AIDS. In: **Oncology Therapeutics: A Quick**

- Reference Guide.** Tempero M, Ratain M (ed). WB Saunders, Philadelphia, 2001, pp 205-208.
8. **Sparano JA**, Kalkut G. Special Considerations Regarding Antiretroviral Therapy and Infection Prophylaxis in the HIV-Infected Individual with Cancer. In, **Sparano JA** (ed). **Cancer Treatment and Research: HIV-Associated Malignancies**. Kluwer Academic Publishers, Norwell, MA, 2001, pp 347-366.
  9. Ambinder RA, **Sparano JA**. Primary central nervous system lymphoma. In, **Sparano JA** (ed). **Cancer Treatment and Research: HIV-Associated Malignancies**. Kluwer Academic Publishers, Norwell, MA, 2001, pp 231-250.
  10. **Sparano JA**. Cytotoxic Therapy for Metastatic Breast Cancer. In: Pasqualini J. Breast Cancer: Prognosis, Prevention, and Treatment. Marcel Dekker, New York, New York, 2002, pp 417-472.
  11. Malik U, **Sparano JA**. Management of Locally Advanced Breast Cancer. In: Pasqualini J. Breast Cancer: Prognosis, Prevention, and Treatment. Marcel Dekker, New York, New York, 2002, pp473-496.
  12. Akerele C, **Sparano JA**. Dyspnea. In: Furie B, Mayer RJ, Cassileth PA, Atkins MB (eds) Clinical Hematology and Oncology: Presentation, Diagnosis, and Treatment. Churchill Livingstone, Elsevier Inc, USA, 2003, pp 75-80.
  13. Parekh S, **Sparano JA**. Clinical Aspects of Human Immunodeficiency Virus-Associated Lymphoma. **Progress in AIDS Research**: 2005, pp 1-31.
  1. **Etkind P**, **Sparano JA**. Prevention of breast cancer. In: Roses DF (ed). Breast Cancer (2<sup>nd</sup> edition). Elsevier, Churchill Livingstone, 2005, pp 58-73.
  14. Parekh S, **Sparano JA**. Primary Effusion Lymphomas: Biology and Management. In: Volberding P, Palefsky J. Virally Mediated Malignancies 2006; pp 122-129.
  15. **Sparano JA**. TAILORx: Rationale for the study design. In Leyland-Jones B (ed). Pharmacogenetics of Breast Cancer: Towards Individualization of Therapy. Informa Health Care, New York, London, 2008, pp 185-196. .
  16. Pellegrino C, **Sparano JA**. Cytotoxic Therapy for Metastatic Breast Cancer. In: Pasqualini J. Breast Cancer: Prognosis, Prevention, and Treatment. Marcel Dekker, New York, New York, 2008.
  17. **Sparano JA**. Management of Operable and Locally Advanced Breast Cancer. In: Pasqualini J. Breast Cancer: Prognosis, Prevention, and Treatment. Marcel Dekker, New York, New York, 20

**ABSTRACTS (oral presentations, first or senior author only):**

1. **Sparano JA**, Micethich KC, Sungerland M, Margolin K, Aronson F, Sznol M, Rubinstein LV. A randomized phase III trial of treatment with high-dose interleukin-2 (IL-2) either alone or in combination with interferon- $\alpha$ 2a (IFN) in patients with advanced melanoma. **ASCO 1993**. Proc Am Soc Clin Oncol 12:390, 1993 (1332).
2. **Sparano JA**, Wiernik PH, Strack M, Leaf A. Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV-and HTLV-I-related non-Hodgkin's lymphoma (NHL): a highly active regimen. **ASCO 1993**. Proc Am Soc Clin Oncol 12:50, 1993 (abstr 3).
3. **Sparano JA**, Wiernik PH, Leaf A, Henry D, Mason B, Sarta C, Hu X, Dutcher JP: Didanosine ameliorates neutropenia in patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide, doxorubicin and etoposide. **AACR 1995**. Proc Am Assoc Cancer Res 36: 203, 1995 (abstr 1207).
4. **Sparano JA**, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E4195). **San Antonio Breast Cancer Symposium 1997**. Breast Cancer Research and Treatment 46: 23, 1997 (abstr 3).
5. **Sparano JA**, Anand K, Mitnick R. Effect of protease inhibitor therapy on the incidence of HIV-associated malignancies at an urban medical center. **International AIDS Malignancy Meeting 1998**. J Human Retrovirol 17; A40, 1998 (abstr S9).
6. **Sparano JA**, Hu P, Schaefer PL, Falkson CI, Wood W. Phase II trial of doxorubicin and docetaxel (Taxotere) plus granulocyte-colony stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group study (E1196). **San Antonio Breast Cancer Symposium 1998**. Breast Cancer Research and Treatment 1998; 50: 233 (abstr 27)
7. Simonelli C, Tirelli U, Spina M, Vaccher E, Jaeger U, **Sparano JA**. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma. **2001 International AIDS Malignancy Conference**, Bethesda, MD, April 23-25. (abstr 22).
8. Moadel A. B., Shah C., Patel S., Wylie-Rosett J., Siedleck H., Porcelli T., Kolidas E., **Sparano J**. Randomized controlled trial of yoga for symptom management during breast cancer treatment. **ASCO 2003**. Proc Am Soc Clin Oncol 22: 726, 2003 (abstr 2921).
9. **Sparano JA**, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. **San Antonio Breast Cancer Symposium 2005** (abstr 48).

10. **Sparano, J. A.**, Wang, M., Martino, S., Jones, V., Perez, E., Saphner, T., Wolff, A. C., Sledge, G. W., Jr, Wood, W. C., Davidson, N. E. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. **ASCO 2007**. Proc Am Soc Clin Oncol 25: 516
11. Goldstein L, Ravdin P, Gray R, Yoshizawa C, Childs B, Rowley S, Shak S, Badve S, Baehner FL, Davidson N, Sledge GW, **Sparano JA**. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. **San Antonio Breast Cancer Symposium 2007** (abst 63)
12. **Sparano JA**, Goldstein, Childs BH, et al. Association of Individual Genes Associated with Recurrence in Operable Breast Cancer Treated with Adjuvant Chemotherapy. **2007 ASCO Breast Cancer Symposium**, San Francisco, CA.
13. **Sparano JA**, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. **San Antonio Breast Cancer Symposium 2008**.
14. **Sparano JA**, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III trial. **San Antonio Breast Cancer Symposium 2008**.
15. **Sparano JA**, Goldstein LJ, Childs BH, Shak S, Badve S, Baehner FL, Davidson NE, Sledge GW, Gray R. Genotypic characterization of phenotypically defined triple-negative breast cancer. **ASCO 2009** (abstract 500, Clinical Science Symposium)
16. **Sparano JA**, Wang W, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson N. Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. **San Antonio Breast Cancer Symposium 2010**, Abstract 34
17. **Sparano JA**, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE. Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment Group. **San Antonio Breast Cancer Symposium 2010**, Abstract S2-1

18. Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, **Sparano JA**, Wood W. A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. **San Antonio Breast Cancer Symposium 2011**, Abstract S4-6